IP Library Granted Patent US 10,370,418
Granted Patent B2
US 10,370,418 · App. 14/717,962 · Granted Aug 6, 2019

Engineered microorganisms having resistance to ionic liquids

Inventors: Michael P. Thelen (Danville, CA); Douglas A. Higgins (Point Pleasant, NJ); Thomas L. Ruegg (Berkeley, CA)
Assignee: Lawrence Livermore National Security, LLC
C07K14/255C07K14/395C12N1/14C12N1/16C12N1/20C12P7/10C12P2203/00Y02E50/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,370,418
App. No.
14/717,962
Granted
Aug 6, 2019
Kind
B2
Abstract

The present invention provides for a method of genetically modifying microorganisms to enhance resistance to ionic liquids using a yeast Major Facilitator Superfamily (MFS), or a Salmonella MFS SmvA Pump or SmvR Regulator, a Small Multidrug Resistance Family (SMR), or Saccharomyces cerevisiae YDR090C, polypeptide, host cells genetically modified in accordance with the methods, and methods of using the host cells in a reaction comprising biomass that has been pretreated with ionic liquids.

Claims (11)

1. A culture medium comprising an ionic liquid and a recombinant microorganism, wherein the microorganism comprises a heterologous gene encoding a polypeptide operably linked to a promoter, wherein the polypeptide has at least 95% identity to one amino acid sequence selected from the group consisting of SEQ ID NOs:1 and 21, and the expression of the polypeptide confers to the microorganism resistance to the concentration of the ionic liquid in the culture medium.

2. The culture medium of claim 1 , wherein the polypeptide has at least 99% identity to one amino acid sequence selected from the group consisting of SEQ ID NOs:1 and 21.

3. The culture medium of claim 1 , wherein the polypeptide comprises at least 95% identity to SEQ ID NO:21 and the polypeptide comprises a proline at a position corresponding to position 282 of SEQ ID NO:21, a leucine at a position corresponding to position 284 of SEQ ID NO:21, or both.

4. The culture medium of claim 1 , wherein the heterologous gene is operably linked to a tet repressor sequence.

5. The culture medium of claim 1 , wherein the microorganism is a bacteria.

6. The culture medium of claim 5 , wherein the bacteria is Escherichia coli.

7. The culture medium of claim 1 , wherein the microorganism is a yeast or filamentous fungi.

8. The culture medium of claim 1 , wherein the anion of the ionic liquid is Cl − or acetate.

9. The culture medium of claim 1 , wherein the heterologous gene encoding the polypeptide is on a vector or is integrated into the genome of the microorganism.

10. The culture medium of claim 1 , wherein the culture medium further comprises a biomass.

11. The culture medium of claim 1 , wherein the culture medium comprises about 1% to about 20% of the ionic liquid.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 1, 2020
From: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 053667/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2015
From: THELEN, MICHAEL P.; HIGGINS, DOUGLAS A.; RUEGG, THOMAS L.
To: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Reel/Frame 036524/0899 →
CONFIRMATORY LICENSE Recorded Aug 11, 2015
From: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 036354/0554 →
Continuity (2)
Provisional Application 62001014 · May 20, 2014
Related Publication 20160090405A1 · Mar 31, 2016